Key Points
- Director Jeffrey Dunn sold 20,000 SiBone shares for $417,800 at an average price of $20.89, reducing his stake by 55.47% to 16,057 shares.
- SiBone’s latest quarter beat expectations: it posted a loss of $0.08 per share versus the $0.13 loss forecast and revenue of $55.7 million versus $55.31 million expected.
- Analyst sentiment remained broadly positive, with seven Buy ratings and one Sell rating and a consensus price target of $25; several firms recently raised their targets.
SiBone (NASDAQ:SIBN - Get Free Report) Director Jeffrey Dunn sold 20,000 shares of the business's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $20.89, for a total value of $417,800.00. Following the completion of the transaction, the director directly owned 16,057 shares of the company's stock, valued at approximately $335,430.73. This trade represents a 55.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
SiBone Trading Up 5.0%
SIBN opened at $24.95 on Thursday. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -80.48 and a beta of 0.64. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92. The company has a 50-day simple moving average of $19.61 and a 200 day simple moving average of $16.52.
SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. Analysts predict that SiBone will post -0.40 EPS for the current fiscal year.
Analyst Ratings Changes
SIBN has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 20th. Needham & Company LLC cut their target price on SiBone from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Tuesday. TD Cowen upped their target price on SiBone from $20.00 to $23.00 and gave the stock a "buy" rating in a research note on Tuesday. Truist Financial raised their target price on SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, October 14th. Finally, UBS Group lifted their price target on SiBone from $25.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $25.00.
Get Our Latest Stock Report on SiBone
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. First Light Asset Management LLC boosted its stake in shares of SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock valued at $132,649,000 after purchasing an additional 2,774,795 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of SiBone by 41.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after purchasing an additional 182,465 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of SiBone by 101.6% during the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after purchasing an additional 238,219 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of SiBone by 40.3% during the 2nd quarter. Squarepoint Ops LLC now owns 118,128 shares of the company's stock valued at $1,928,000 after purchasing an additional 33,947 shares during the last quarter. Finally, Granahan Investment Management LLC increased its position in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after purchasing an additional 858,942 shares in the last quarter. Institutional investors own 98.11% of the company's stock.
Key SiBone News
Here are the key news stories impacting SiBone this week:
- Positive Sentiment: Q3 results topped estimates. SiBone reported a loss of $0.08 per share, narrower than analysts’ expected $0.13 loss, and revenue of $55.7 million versus $55.3 million expected. Q3 earnings report
- Positive Sentiment: Analysts raised price targets and maintained Buy ratings. UBS lifted its target to $26 from $25, while TD Cowen raised its target to $23 from $20. These revisions indicate continued analyst support, although TD Cowen’s target is below the recent share price. UBS ratings TD Cowen ratings
- Neutral Sentiment: 2026 revenue guidance was reaffirmed. SiBone forecast full-year revenue of $231 million to $233 million, broadly in line with the $232.2 million consensus estimate, providing little change to expectations. Company Q3 results and guidance
- Negative Sentiment: Two insiders sold shares. Director Jeffrey W. Dunn sold 20,000 shares, cutting his stake by 55.47%; insider Anshul Maheshwari sold 3,738 shares. Insider selling can weigh on sentiment, though both retained shares after their transactions. Dunn SEC filing Maheshwari transaction details
About SiBone
(
Get Free Report)
SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.
Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
